ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,667.20
0.64%
US Tech 100
19,853.60
0.00%
Dow Jones
40,954.48
1.85%
Brent Oil
83.44
0.15%
Bitcoin
65,393.05
0.46%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Neurogene Inc (NGNE)

  7. Neurogene Inc (NGNE) News

NGNE

Neurogene (NGNE)

Neurogene Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NGNE
DateTimeSourceHeadlineSymbolCompany
07/02/20247:30AMBusiness WireNeurogene to Participate in BMO Genetic Medicines SummitNASDAQ:NGNENeurogene Inc
07/01/20247:30AMBusiness WireNeurogene Announces Addition to Russell 3000® IndexNASDAQ:NGNENeurogene Inc
06/18/20249:26AMBusiness WireNeurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett SyndromeNASDAQ:NGNENeurogene Inc
06/05/20247:30AMBusiness WireNeurogene to Participate in Upcoming ConferencesNASDAQ:NGNENeurogene Inc
06/03/20247:30AMBusiness WireNeurogene Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for START Pilot ProgramNASDAQ:NGNENeurogene Inc
05/10/20247:30AMBusiness WireNeurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
05/07/20246:19AMBusiness WireNeurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingNASDAQ:NGNENeurogene Inc
04/22/20244:36PMBusiness WireNeurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT MeetingNASDAQ:NGNENeurogene Inc
03/18/20244:14PMBusiness WireNeurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent UpdatesNASDAQ:NGNENeurogene Inc
03/04/20247:30AMBusiness WireNeurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical TrialNASDAQ:NGNENeurogene Inc
02/29/20247:30AMBusiness WireNeurogene to Participate in Upcoming Investor ConferencesNASDAQ:NGNENeurogene Inc
01/16/20247:00AMBusiness WireNeurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerNASDAQ:NGNENeurogene Inc
01/05/20247:00AMBusiness WireNeurogene Announces Business Update and 2024 OutlookNASDAQ:NGNENeurogene Inc
 Showing the most relevant articles for your search:NASDAQ:NGNE

Your Recent History

USOTC
KITL
Kisses from Italy (QB)
USOTC
CLNV
Clean Vision (QB)
USOTC
UBQU
Ubiquitech Software (PK)
COIN
XRPUSD
Ripple
USOTC
RNVA
Rennova Health (PK)
NASDAQ
COOP
Mr Cooper
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
NYSE
GME
GameStop
USOTC
ENZC
Enzolytics (PK)
USOTC
HIRU
Hiru (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
AXXA
Exxe (PK)
AMEX
SPY
SPDR S&P 500
USOTC
SMCE
SMC Entertainment (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
RDGL
Vivos (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved